These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
477 related articles for article (PubMed ID: 36410364)
1. Safety of the fourth COVID-19 BNT162b2 mRNA (second booster) vaccine: a prospective and retrospective cohort study. Yechezkel M; Mofaz M; Painsky A; Patalon T; Gazit S; Shmueli E; Yamin D Lancet Respir Med; 2023 Feb; 11(2):139-150. PubMed ID: 36410364 [TBL] [Abstract][Full Text] [Related]
2. Safety of monovalent and bivalent BNT162b2 mRNA COVID-19 vaccine boosters in at-risk populations in Israel: a large-scale, retrospective, self-controlled case series study. Yamin D; Yechezkel M; Arbel R; Beckenstein T; Sergienko R; Duskin-Bitan H; Yaron S; Peretz A; Netzer D; Shmueli E Lancet Infect Dis; 2023 Oct; 23(10):1130-1142. PubMed ID: 37352878 [TBL] [Abstract][Full Text] [Related]
3. Comparison of physiological and clinical reactions to COVID-19 and influenza vaccination. Yechezkel M; Qian G; Levi Y; Davidovitch N; Shmueli E; Yamin D; Brandeau ML Commun Med (Lond); 2024 Aug; 4(1):169. PubMed ID: 39181950 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of potential adverse events following COVID-19 mRNA vaccination among adults aged 65 years and older: Two self-controlled studies in the U.S. Shoaibi A; Lloyd PC; Wong HL; Clarke TC; Chillarige Y; Do R; Hu M; Jiao Y; Kwist A; Lindaas A; Matuska K; McEvoy R; Ondari M; Parulekar S; Shi X; Wang J; Lu Y; Obidi J; Zhou CK; Kelman JA; Forshee RA; Anderson SA Vaccine; 2023 Jul; 41(32):4666-4678. PubMed ID: 37344261 [TBL] [Abstract][Full Text] [Related]
5. COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study. Menni C; May A; Polidori L; Louca P; Wolf J; Capdevila J; Hu C; Ourselin S; Steves CJ; Valdes AM; Spector TD Lancet Infect Dis; 2022 Jul; 22(7):1002-1010. PubMed ID: 35405090 [TBL] [Abstract][Full Text] [Related]
6. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study. Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD; Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524 [TBL] [Abstract][Full Text] [Related]
7. Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and Wales. Agrawal U; Bedston S; McCowan C; Oke J; Patterson L; Robertson C; Akbari A; Azcoaga-Lorenzo A; Bradley DT; Fagbamigbe AF; Grange Z; Hall ECR; Joy M; Katikireddi SV; Kerr S; Ritchie L; Murphy S; Owen RK; Rudan I; Shah SA; Simpson CR; Torabi F; Tsang RSM; de Lusignan S; Lyons RA; O'Reilly D; Sheikh A Lancet; 2022 Oct; 400(10360):1305-1320. PubMed ID: 36244382 [TBL] [Abstract][Full Text] [Related]
8. Self-Reported and Physiologic Reactions to Third BNT162b2 mRNA COVID-19 (Booster) Vaccine Dose. Mofaz M; Yechezkel M; Guan G; Brandeau ML; Patalon T; Gazit S; Yamin D; Shmueli E Emerg Infect Dis; 2022 Jul; 28(7):1375-1383. PubMed ID: 35654410 [TBL] [Abstract][Full Text] [Related]
9. Surveillance of Safety of 3 Doses of COVID-19 mRNA Vaccination Using Electronic Health Records. Niesen MJM; Pawlowski C; O'Horo JC; Challener DW; Silvert E; Donadio G; Lenehan PJ; Virk A; Swift MD; Speicher LL; Gordon JE; Geyer HL; Halamka JD; Venkatakrishnan AJ; Soundararajan V; Badley AD JAMA Netw Open; 2022 Apr; 5(4):e227038. PubMed ID: 35420661 [TBL] [Abstract][Full Text] [Related]
10. Safety of heterologous primary and booster schedules with ChAdOx1-S and BNT162b2 or mRNA-1273 vaccines: nationwide cohort study. Andersson NW; Thiesson EM; Laursen MV; Mogensen SH; Kjær J; Hviid A BMJ; 2022 Jul; 378():e070483. PubMed ID: 35831006 [TBL] [Abstract][Full Text] [Related]
11. Short term, relative effectiveness of four doses versus three doses of BNT162b2 vaccine in people aged 60 years and older in Israel: retrospective, test negative, case-control study. Gazit S; Saciuk Y; Perez G; Peretz A; Pitzer VE; Patalon T BMJ; 2022 May; 377():e071113. PubMed ID: 35609888 [TBL] [Abstract][Full Text] [Related]
12. Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore. Ng OT; Marimuthu K; Lim N; Lim ZQ; Thevasagayam NM; Koh V; Chiew CJ; Ma S; Koh M; Low PY; Tan SB; Ho J; Maurer-Stroh S; Lee VJM; Leo YS; Tan KB; Cook AR; Tan CC JAMA Netw Open; 2022 Aug; 5(8):e2228900. PubMed ID: 36018588 [TBL] [Abstract][Full Text] [Related]
13. Odds of Testing Positive for SARS-CoV-2 Following Receipt of 3 vs 2 Doses of the BNT162b2 mRNA Vaccine. Patalon T; Gazit S; Pitzer VE; Prunas O; Warren JL; Weinberger DM JAMA Intern Med; 2022 Feb; 182(2):179-184. PubMed ID: 34846533 [TBL] [Abstract][Full Text] [Related]
14. Comparative Safety of BNT162b2 and mRNA-1273 Vaccines in a Nationwide Cohort of US Veterans. Dickerman BA; Madenci AL; Gerlovin H; Kurgansky KE; Wise JK; Figueroa Muñiz MJ; Ferolito BR; Gagnon DR; Gaziano JM; Cho K; Casas JP; Hernán MA JAMA Intern Med; 2022 Jul; 182(7):739-746. PubMed ID: 35696161 [TBL] [Abstract][Full Text] [Related]
15. Association of a Third Dose of BNT162b2 Vaccine With Incidence of SARS-CoV-2 Infection Among Health Care Workers in Israel. Spitzer A; Angel Y; Marudi O; Zeltser D; Saiag E; Goldshmidt H; Goldiner I; Stark M; Halutz O; Gamzu R; Slobodkin M; Amrami N; Feigin E; Elbaz M; Furman M; Bronstein Y; Chikly A; Eshkol A; Furer V; Mayer T; Meijer S; Melloul A; Mizrahi M; Yakubovsky M; Rosenberg D; Safir A; Spitzer L; Taleb E; Elkayam O; Silberman A; Eviatar T; Elalouf O; Levinson T; Pozyuchenko K; Itzhaki-Alfia A; Sprecher E; Ben-Ami R; Henig O JAMA; 2022 Jan; 327(4):341-349. PubMed ID: 35006256 [TBL] [Abstract][Full Text] [Related]
16. Infections, hospitalisations, and deaths averted via a nationwide vaccination campaign using the Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine in Israel: a retrospective surveillance study. Haas EJ; McLaughlin JM; Khan F; Angulo FJ; Anis E; Lipsitch M; Singer SR; Mircus G; Brooks N; Smaja M; Pan K; Southern J; Swerdlow DL; Jodar L; Levy Y; Alroy-Preis S Lancet Infect Dis; 2022 Mar; 22(3):357-366. PubMed ID: 34562375 [TBL] [Abstract][Full Text] [Related]
17. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial. Akova M; Unal S Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629 [TBL] [Abstract][Full Text] [Related]
18. Postmarketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12 to 39 years in Italy: A multi-database, self-controlled case series study. Massari M; Spila Alegiani S; Morciano C; Spuri M; Marchione P; Felicetti P; Belleudi V; Poggi FR; Lazzeretti M; Ercolanoni M; Clagnan E; Bovo E; Trifirò G; Moretti U; Monaco G; Leoni O; Da Cas R; Petronzelli F; Tartaglia L; Mores N; Zanoni G; Rossi P; Samez S; Zappetti C; Marra AR; Menniti Ippolito F; PLoS Med; 2022 Jul; 19(7):e1004056. PubMed ID: 35900992 [TBL] [Abstract][Full Text] [Related]
19. Comparative Risks of Potential Adverse Events Following COVID-19 mRNA Vaccination Among Older US Adults. Harris DA; Hayes KN; Zullo AR; Mor V; Chachlani P; Deng Y; McCarthy EP; Djibo DA; McMahill-Walraven CN; Gravenstein S JAMA Netw Open; 2023 Aug; 6(8):e2326852. PubMed ID: 37531110 [TBL] [Abstract][Full Text] [Related]
20. Risk of myocarditis and pericarditis after the COVID-19 mRNA vaccination in the USA: a cohort study in claims databases. Wong HL; Hu M; Zhou CK; Lloyd PC; Amend KL; Beachler DC; Secora A; McMahill-Walraven CN; Lu Y; Wu Y; Ogilvie RP; Reich C; Djibo DA; Wan Z; Seeger JD; Akhtar S; Jiao Y; Chillarige Y; Do R; Hornberger J; Obidi J; Forshee R; Shoaibi A; Anderson SA Lancet; 2022 Jun; 399(10342):2191-2199. PubMed ID: 35691322 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]